Solid Biosciences Inc. — Cyborg Score 5/10

Mixed
Biotechnology / Precision Gene Therapy

Strategic Profile

The company is involved in developing platform technologies, including capsid libraries, genetic regulators such as promoters, UTRs, and introns, immunomodulation technologies, manufacturing purity, and dual gene expression, a technology for packaging multiple transgenes into one capsid. Founded by those directly impacted by Duchenne, Solid's mission is to improve the daily lives of patients living with devastating rare diseases.

Cyborg Score Rationale

While SLDB has a great health rating, there are worries on its profitability. February brought positive FDA Type C feedback for SGT-003's Phase 3 IMPACT DUCHENNE trial, with 36 Phase 1/2 participants dosed. The company shows clinical progress but faces profitability challenges as a pre-revenue biotech.

Top Insights

  • Lead program SGT-003 for Duchenne muscular dystrophy advancing in Phase 1/2 with recent FDA positive feedback for Phase 3 trial
  • Diversified pipeline across rare neuromuscular and cardiac indications reducing single-program risk
  • Proprietary platform technologies (capsid libraries, genetic regulators) provide potential cross-industry licensing opportunities
  • Early profitability concerns with negative EPS of -$2.49 per share over trailing twelve months

Named Competitors

  • Gene therapy for Duchenne muscular dystrophy — Established gene therapy player in neuromuscular diseases
  • AAV-based gene therapy platform — Gene therapy platform provider focusing on rare genetic diseases
  • Gene therapy programs — Genetic medicine company with rare disease focus

Recent Developments

  • (January 2026) FDA Orphan Drug designation and first dosing in FALCON trial for SGT-212
  • (February 2026) Positive FDA Type C feedback for SGT-003 Phase 3 IMPACT DUCHENNE trial
  • (January 2026) Over 50 AAV-SLB101 agreements announced with 12.6% stock gain

Open the full interactive Solid Biosciences Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →